Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia

SABR Symposium 2026









CONVENOR WELCOME MESSAGE

Thank you for joining us at the Peter MacCallum Cancer Centre SABR Symposium 2026. This symposium is designed for the three disciplines that are fundamental to the safe and effective delivery of SABR: radiation oncologists, radiation therapists and medical physicists. As the use of SABR continues to expand across a growing range of disease sites and clinical settings, it has attracted interest from a broader community of cancer clinicians, researchers and healthcare professionals.

This year we are grateful to our outstanding international faculty who have joined us in Melbourne to share their expertise and experience, namely Dr Houda Bahig (Canada), Dr Melvin Chua (Singapore), Professor Stefanie Corradini (Germany), Patty Díez (United Kingdom) and Dr David Palma (Canada).

Following the success of previous years, we are returning to the Bio21 Institute in Melbourne's renowned biomedical precinct. We are also delighted to welcome delegates to the beautiful Victorian Comprehensive Cancer Centre building that houses Peter Mac on Friday evening for our Welcome Reception, where you can share a drink, reconnect with friends and colleagues, and enjoy sweeping views across Royal Park and Melbourne's northern and western skyline.

We hope you enjoy the educational program and interactive discussions planned over the next two days, and that the Symposium provides valuable insights, practical knowledge and new perspectives that will continue to advance the delivery of SABR.



Prof Shankar Siva
Convenor, on behalf of the Organising Committee

ORGANISING COMMITTEE

Melissa Barber
Mark Burns
Becky Castle
Sarat Chander
Steven David
Tom Devereux
Lisa Hall
Nick Hardcastle
Tomas Kron
Andrew Lim
Kubilay Mulayim
Sally Soteriou
Mark Shaw
Kenton Thompson
Katrina Woodford
Adam Yeo

PROGRAM

FRIDAY 20TH NOVEMBER

TIME	EVENT	SPEAKER
0815	**REGISTRATION**	
0900	Acknowledgement of Country & Welcome Address	**Dr Jason Payne, Dr Belinda Campbell, Dr Shankar Siva**
	SESSION 1: Sponsored by Siemens Healthineers	**Chaired by Dr Shankar Siva**
0910	Oligometastatic Cancers – What We've Learned from 15 Years of Clinical Trials	**Dr David Palma**
0950	The Biology of SABR in Modern Oncology	**Dr Melvin Chua**
1030	**Morning Tea Sponsored by Raysearch**	
	SESSION 2	**Chaired by Dr Nick Hardcastle**
1100	Precision at Scale: A Blueprint for National SABR Rollout	**Ms Patty Díez**
1140	**Interactive Session #1:** Look Mum, no hands! AI-led SABR, what could possibly go wrong?	**Facilitators:** Dr Nick Hardcastle and Mr Mark Burns
1240	**Group Photo**	**Atrium Foyer**
1300	**Lunch Break**	
	SESSION 3: Sponsored by Brainlab	**Chaired by Dr Tomas Kron**
1400	One and Done? Single-Fraction SABR for Liver Tumours	**Dr Stefanie Corradini**
1440	**Expert Panel Discussion #1** How do we use SABR in a pre-treated patient	**Moderators:** Dr Tomas Kron & Dr Shankar Siva (with our 5 International Speakers)
1520	**Afternoon Tea Sponsored by Cipla**	
	SESSION 4: Sponsored by Elekta	**Chaired by Dr Sarat Chander**
1550	Risky Business of Safe SBRT in Ultracentral Tumours and Interstitial Lung Disease	**Dr Houda Bahig**
1630–1720	Debate Inside out or Outside in? The death of brachytherapy has been exaggerated	**Affirmative:** Dr Stefanie Corradini **Negative:** Dr David Palma
1730–1930	**Welcome Reception The Rutherford Room Level 13, Peter MacCallum Cancer Centre, 305 Grattan St, Parkville**	

PROGRAM

SATURDAY 21ST NOVEMBER

TIME	EVENT	SPEAKER
	SESSION 5	**Chaired by Dr Adam Yeo**
0900	From Niche to Nationwide: Technology's Role in Transforming SABR in the UK	**Ms Patty Díez**
0940	Straight to the Heart: Pushing the Boundaries of SABR	**Dr Stefanie Corradini**
1020	**Morning Tea Sponsored by Mundipharma**	
	SESSION 6: Sponsored by AlphaXRT	**Chaired by Dr Katrina Woodford**
1100	Thirty-Five Fractions Is a Lot of Parking, or the Case for Head and Neck SBRT	**Dr Houda Bahig**
1140	SABR in Prostate Cancer	**Dr Melvin Chua**
1220	**Expert Panel Discussion #2** Balancing Evidence, Innovation & Implementation	**Moderators:** Dr Tomas Kron & Dr Shankar Siva (with our 5 International Speakers)
1300	**Lunch Break**	
	SESSION 7	**Chaired by Mr Kenton Thompson**
1400	**Interactive Session #2:** What would you do? Managing difficult cases	**Facilitators:** Dr Adam Yeo, Dr Katrina Woodford, Dr Mark Shaw
1500	SABR in 2036: How Will We Be Practicing 10 Years from Now	**Dr David Palma**
1540	Summary and Closing Comments	**Dr Shankar Siva**
1600	**Symposium Close**	

INTERNATIONAL FACULTY



HOUDA BAHIG
L'UNIVERSITÉ DE MONTRÉAL, CANADA

Dr Houda Bahig, MD, PhD, is a radiation oncologist at the Centre hospitalier de l'Université de Montréal and Associate Professor at Université de Montréal. She specializes in SBRT and precision radiation oncology, with a focus on head and neck and lung cancers.

Dr Bahig leads multiple investigator-initiated clinical trials evaluating head and neck SBRT, treatment de-escalation strategies, adaptive radiotherapy, immuno-radiotherapy combinations, and radiotherapy in patients with interstitial lung disease. She also leads a translational research laboratory whose program integrates radiomics, artificial intelligence, and multi-omics biomarkers to personalize radiation treatment, reduce toxicity, and optimize oncologic outcomes.

INTERNATIONAL FACULTY



MELVIN CHUA
NATIONAL CANCER CENTRE, SINGAPORE

Dr Chua is a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. He is the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP), and Director of the Data and Computational Science Hub at NCCS. He is currently Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; and Visiting Professor of the Zhongnan Hospital of Wuhan University, China.

His work is supported by several National grants including: (1) the NMRC CSA (Senior Investigator-category); (2) the NMRC Open Fund Large Collaborative Grant (OF-LCG); and (3) the NMRC Centre Grant, as well as large philanthropic donations, notably from the Goh Foundation to Proton Therapy Research, the Tibore Foundation to the Kua Hong Pak Head and Neck Cancer Research Programme, and the Singapore Rubber Miller Association to the Cancer and Data Science Programme. His key research focus areas are: (1) Developing a comprehensive nasopharyngeal carcinoma clinical and translational research programme that leverages on innovative designs of phase 2-3 trials, a multi-dimensional, deeply-annotated clinical-molecular database, coupled with broad-scale computational genomics approaches for biomarker discoveries; and (2) A translational radiation research programme that leverages bench-to-bedside expertise to understand the mechanistic pathways of radiation resistance, and to develop new treatment regimens to target these molecular vulnerabilities.

INTERNATIONAL FACULTY



STEFANIE CORRADINI
FAU ERLANGEN-NÜRNBERG, GERMANY

Prof Stefanie Corradini, MD, is a radiation oncologist and Professor of Radiotherapy at the Friedrich-Alexander-University Erlangen-Nürnberg (FAU), where she has served since October 2025 as Director of the Department of Radiation Oncology and Chair of Radiotherapy.

Prof Corradini is internationally recognised for her expertise in MR-guided radiotherapy, high-precision stereotactic treatments (SABR/SBRT), and brachytherapy, and has contributed to advancing treatment of complex or inoperable cancers through novel high-dose, image-guided approaches that maximise tumour control while minimising toxicity. She has led major research efforts, including the world's largest study on radiotherapy for cardiac tumours, and continues to collaborate internationally on innovations in motion management, automation, and AI-supported radiation therapy.

Her research portfolio spans clinical radiation oncology, MR-guided therapy development, high-risk lung SABR, and image-guided brachytherapy, with numerous publications across high-impact journals and contributions to field-defining textbooks. Recent work includes leading a multi-institutional analysis of single-fraction MR-guided SABR demonstrating excellent local control with low toxicity.

Prof Corradini is a strong advocate for integrating cutting-edge technology with personalised, compassionate patient care. She is widely regarded as one of Europe's leading next-generation clinical innovators in advanced radiotherapy.

INTERNATIONAL FACULTY



PATRICIA (PATTY) DÍEZ

NATIONAL RADIOTHERAPY TRIALS QUALITY ASSURANCE GROUP, UK

Patty Díez is a medical physicist who trained at Mount Vernon Cancer Centre and has worked in the National Radiotherapy Trials Quality Assurance (RTTQA) Group for over 20 years, striving to standardise treatment and raise radiotherapy standards through clinical trials. As lead clinical scientist in RTTQA, she has developed QA programmes for numerous trials for various indications including haematological malignancies, cervical cancer and oligometastatic disease. Patty's current focus is on SABR trials (including STAMPEDE2, HALT, SOPRANO and TRAP) whilst leading the national SABR implementation programme.

Patty is an active member of the UK SABR Consortium Executive Committee, the UK SABR Education Working Group, the Global Harmonization Group and co-chairs the UK Haematology Radiotherapy Group. She is the editor of the UK SABR Consortium Guidelines and has recently co-authored the RCR Guidance on auto-contouring in radiotherapy. Patty is also contributing to the ESTRO consensus guidelines for the technical requirements for SABR as well as for the use of auto-segmentation in radiation oncology, and has a keen interest in teaching, serving as faculty for the EFOMP SABR MPE courses and all UK SABR Workshops.

INTERNATIONAL FACULTY



DAVID PALMA
WESTERN UNIVERSITY, LONDON, CANADA

Dr David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master's Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, including the SABR-COMET and SABR-COMET10 randomized trials in oligometastatic disease, and the ORATOR and ORATOR2 trials in head and neck cancer. He is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group, which runs pragmatic radiation oncology trials in lung cancer. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.

PROFESSIONAL DEVELOPMENT CREDIT

CPD/CME credits can be claimed from the three peak bodies representing SABR professionals;

Attendance certificates will be issued following the SABR Symposium to enable the necessary claims. Further details are provided below.

ACPSEM CPD Endorsed Activity

ASMIRT CPD ENDORSED

The Royal Australian and New Zealand College of Radiologists®

The Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM)

The 2026 SABR Symposium has been endorsed by ACPSEM and attendees will be able to claim 2 CPD points per hour of the meeting attended, to a maximum of 10 points per day.

The Australian Society of Medical Imaging and Radiation Therapy (ASMIRT)

This event has been granted approval as a professional development activity by ASMIRT. The Appellation number/ unique activity code for the SABR Symposium is PMACCC-003270. For those who attend part of this meeting, CPD hours may be claimed pro rata equivalent to the hours attended.

The Royal Australian and New Zealand College of Radiologists (RANZCR)

CPD hours can be claimed for attendance at the 2026 SABR Symposium. Attendees may claim ~12 CPD hours for attending the full meeting (20th & 21st November). For anyone who attends only part of this meeting, CPD hours may be claimed pro rata equivalent to the hours attended.

SPONSORS

The organising committee wishes to acknowledge the support and thank the following sponsors of the 2026 SABR Symposium

PLATINUM:

alphaXRT
First for excellence in radiation technology

SIEMENS Healthineers

GOLD:

BRAINLAB

Elekta

COFFEE CART PARTNER:

nltec SINCE 1994

BRONZE:

RaySearch Laboratories

Cipla

mundipharma

We are grateful for support from Bio21, providing us with access to this venue for the Symposium.

THE UNIVERSITY OF MELBOURNE

bio21 institute

WELCOME RECEPTION AND NETWORKING DRINKS


PLEASE JOIN US!!

Following the SABR Symposium Debate the Organising Committee will host a Networking Function. This evening will provide delegates with a great opportunity to reconnect with colleagues and friends while admiring the great view!

5:30 - 7:30pm
Friday 20 November

The Rutherford Room
Peter MacCallum Cancer Centre

An easy 5 minute stroll from the Symposium lecture theatre.



SPEAKER ABSTRACTS

FRIDAY 20TH NOVEMBER

Oligometastatic Cancers – What We've Learned from 15 Years of Clinical Trials

Dr David Palma

This talk will review the history of oligometastatic cancers, and the top lessons learned that can inform our clinical practice today. The talk will discuss patient selection, doses, pearls for treatment planning, and the newest biomarkers that may soon be guiding treatment.

The Biology of SABR in Modern Oncology

Dr Melvin Chua

Modern-day oncology calls for multidisciplinary management and integration of local and systemic therapies in both locoregionally-advanced and recurrent-metastatic settings.

SABR is more than just a local ablative tool and offers unique biology that can be leveraged across multiple indications.

He will speak on specific scenarios where SABR could offer therapeutic advantages – countering radioresistance; targeting oligoprogressive disease; and how best to deploy in combination with immunotherapy to exploit synergistic interactions.

Precision at Scale: A Blueprint for National SABR Rollout

Ms Patty Díez

England has a well-established track record of introducing new radiotherapy technologies and techniques through clinical trials, national implementation programmes and robust quality assurance (QA) frameworks. One notable example is the National Health Service England (NHSE) SABR programme. Initially, NHSE funded 18 centres to implement SABR through a comprehensive accreditation process that included contouring and planning benchmark cases, prospective case review and dosimetry audit. Building on this foundation, a subsequent national rollout programme paired experienced centres with those developing new services, supporting implementation through mentorship and peer review. Delivered by a large multidisciplinary team, this initiative has successfully accredited all 51 radiotherapy centres in England for lung, bone and nodal SABR, with credentialing for additional indications ongoing. The presentation will describe the development, delivery and outcomes of the programme, highlighting key lessons from the national rollout and the role of QA in supporting safe and consistent implementation at scale.

RETURN TO FRIDAY 20TH NOVEMBER PROGRAM

SPEAKER ABSTRACTS

FRIDAY 20TH NOVEMBER

One and Done? Single-Fraction SABR for Liver Tumours — **Dr Stefanie Corradini**

Single-fraction SABR promises maximum treatment efficiency and ablative potential – but is one fraction always the best approach? This talk will explore the evidence for single-fraction SABR in primary and metastatic liver tumours, focusing on patient selection, lesion location and optimal dose. Practical cases will highlight the importance of motion management, image guidance and protection of the healthy liver tissue and adjacent luminal organs.

Risky Business of Safe SBRT in Ultracentral Tumours and Interstitial Lung Disease — **Dr Houda Bahig**

This talk addresses the two situations in which lung SBRT carries a meaningful risk of treatment-related death, ultracentral tumours and interstitial lung disease. The objectives are to review the toxicity data and the dose de-escalation, fractionation and adaptive strategies proposed for ultracentral disease, and to describe the risk factors and dosimetric predictors of pneumonitis that inform SBRT in ILD. The published literature is reviewed along with ongoing trials, and a framework for weighing the competing risks of treatment in these patients is proposed.

RETURN TO FRIDAY 20TH NOVEMBER PROGRAM

SPEAKER ABSTRACTS

SATURDAY 21ST NOVEMBER

From Niche to Nationwide: Technology's Role in Transforming SABR in the UK — **Ms Patty Díez**

A small number of UK centres began delivering SABR as early as 2005, supported by access to dedicated treatment platforms such as CyberKnife. Over the following two decades, SABR evolved from a specialist technique offered in a limited number of centres to an established treatment option delivered across the UK. This growth has been underpinned by advances across the patient pathway, including improvements in imaging, motion management, treatment planning, image guidance and treatment delivery. Together, these developments have enhanced the precision, efficiency and reproducibility of SABR, enabling the safe and consistent delivery of the high doses and steep dose gradients required for tumour ablation while minimising toxicity. Technological innovation has also supported wider patient access and the expansion of clinical indications, helping to establish SABR as an increasingly important component of modern radiotherapy practice in the UK.

Straight to the Heart: Pushing the Boundaries of SABR — **Dr Stefanie Corradini**

Primary and secondary cardiac malignancies are rare, clinically challenging and often considered unsuitable for local treatment. This talk will examine the emerging role of SABR as a non-invasive treatment option, including the available clinical evidence, patient selection and realistic therapeutic goals. Practical challenges such as cardiac and respiratory motion, dose prescription and protection of critical cardiac structures will be discussed.

Thirty-Five Fractions Is a Lot of Parking, or the Case for Head and Neck SBRT — **Dr Houda Bahig**

Stereotactic body radiotherapy has moved from a salvage option for recurrent head and neck cancer to prospective evaluation in the definitive, boost and oligometastatic settings. This talk reviews the published literature in each setting, including toxicity and the technical requirements specific to the head and neck. Practical aspects of planning and delivery are discussed, along with lessons drawn from the shared experience of centres practising head and neck SBRT. Ongoing trials are reviewed; randomised evidence remains however limited, and the questions to be answered before SBRT enters routine practice are outlined.

RETURN TO SATURDAY 21ST NOVEMBER PROGRAM

SPEAKER ABSTRACTS

SATURDAY 21ST NOVEMBER

SABR in Prostate Cancer — **Dr Melvin Chua**

SABR has become the standard of care in the treatment of both localised and metastatic prostate cancer.

While PACE-B established SABR prostate as a regimen of equipoise compared to conventional fractionation in the treatment of prostate alone, the field is advancing to expand its applications to more clinical scenarios including simultaneous treatment of the pelvis in advanced disease and re-irradiation of local failures.

Clinical genomics is also an exciting angle where it could enhance the precision of SABR in prostate cancer.

SABR in 2036: How Will We Be Practicing 10 Years from Now — **Dr David Palma**

This talk will discuss the emerging areas of treatment, how our practice will change in the next decade, and how we can best prepare ourselves and our specialty for the future of SABR.

RETURN TO SATURDAY 21ST NOVEMBER PROGRAM